Neocate Junior (amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides)
amino acid formula with fat, carbohydrate, vitamins, minerals, trace elements and medium chain triglycerides powder for oral liquid, 400 g · ORAL · PBS code 11161K
AUTHORITY_REQUIREDWhat it costs
AU$37.19 PBS-determined price per 8 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2017-09-01.
- • Repeats: 5.
- • PBS program: GE.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Cows' milk protein enteropathy
Initial treatment for up to 6 months
Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist; AND
The condition must not be isolated infant colic or reflux; AND
Patient must be intolerant to both soy protein and protein hydrolysate formulae, as demonstrated when the child has failed to respond to a strict cows' milk protein free and strict soy protein free diet with a protein hydrolysate (with or without medium chain triglycerides) as the principal formula; AND
Patient must be up to the age of 24 months.
The name of the specialist and the date of birth of the patient must be included in the authority application.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Severe cows' milk protein enteropathy with failure to thrive
Initial treatment for up to 6 months
Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist; AND
The condition must not be isolated infant colic or reflux; AND
Patient must be up to the age of 24 months.
The name of the specialist and the date of birth of the patient must be included in the authority application.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Combined intolerance to cows' milk protein, soy protein and protein hydrolysate formulae
Initial treatment for up to 6 months
Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist; AND
The condition must not be isolated infant colic or reflux; AND
Patient must be older than 24 months of age.
The name of the specialist and the date of birth of the patient must be included in the authority application.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Proven combined immunoglobulin E (IgE) mediated allergy to cows' milk protein and soy protein
Initial treatment for up to 6 months
Must be treated by a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist, or in consultation with a specialist allergist, clinical immunologist or specialist paediatric gastroenterologist and hepatologist; AND
Patient must have failed a trial of protein hydrolysate formulae (with or without medium chain triglycerides); AND
Patient must be up to the age of 24 months.
The name of the specialist and the date of birth of the patient must be included in the authority application.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Eosinophilic oesophagitis
Initial treatment for up to 3 months
Must be treated by a clinical immunologist, suitably qualified allergist or gastroenterologist; AND
Patient must require an amino acid based formula as a component of a dietary elimination program; AND
Patient must be 18 years of age or less.
Treatment with oral steroids should not be commenced during the period of initial treatment.
Eosinophilic oesophagitis is demonstrated by the following criteria:
(i) Chronic symptoms of reflux that persisted despite a 2-month trial of a proton pump inhibitor or chronic dysphagia; and
(ii) A lack of demonstrable anatomic abnormality with the exception of stricture, which can be attributable to eosinophilic oesophagitis; and
(iii) Eosinophilic infiltration of the oesophagus, demonstrated by oesophageal biopsy specimens obtained by endoscopy and where the most densely involved oesophageal biopsy had 20 or more eosinophils in any single 400 x high powered field, along with normal antral and duodenal biopsies.
The date of birth of the patient must be included in the authority application.
Sponsor: Nutricia Australia Pty Limited ABN 99 076 246 752
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.